TP53 and neoplasm: Subsequently, several pre-clinical trials supported a phase II (NCT05012397) basket study (MANTRA-2) in patients with advanced MDM2amp, TP53-wt solid tumors demonstrating a manageable safety profile and achieved responses against a variety of refractory MDM2amp, TP53-wt solid tumors, but tumor reductions were short-lived [25].